1. Home
  2. VHC vs RNTX Comparison

VHC vs RNTX Comparison

Compare VHC & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VHC
  • RNTX
  • Stock Information
  • Founded
  • VHC 2005
  • RNTX 2001
  • Country
  • VHC United States
  • RNTX United States
  • Employees
  • VHC N/A
  • RNTX N/A
  • Industry
  • VHC Multi-Sector Companies
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • VHC Miscellaneous
  • RNTX Health Care
  • Exchange
  • VHC Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • VHC 35.7M
  • RNTX 40.3M
  • IPO Year
  • VHC 1999
  • RNTX N/A
  • Fundamental
  • Price
  • VHC $8.20
  • RNTX $1.93
  • Analyst Decision
  • VHC
  • RNTX
  • Analyst Count
  • VHC 0
  • RNTX 0
  • Target Price
  • VHC N/A
  • RNTX N/A
  • AVG Volume (30 Days)
  • VHC 3.2K
  • RNTX 51.2K
  • Earning Date
  • VHC 05-14-2025
  • RNTX 05-15-2025
  • Dividend Yield
  • VHC N/A
  • RNTX N/A
  • EPS Growth
  • VHC N/A
  • RNTX N/A
  • EPS
  • VHC N/A
  • RNTX N/A
  • Revenue
  • VHC $3,000.00
  • RNTX N/A
  • Revenue This Year
  • VHC N/A
  • RNTX N/A
  • Revenue Next Year
  • VHC N/A
  • RNTX N/A
  • P/E Ratio
  • VHC N/A
  • RNTX N/A
  • Revenue Growth
  • VHC N/A
  • RNTX N/A
  • 52 Week Low
  • VHC $3.55
  • RNTX $1.35
  • 52 Week High
  • VHC $9.88
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • VHC 49.48
  • RNTX N/A
  • Support Level
  • VHC $7.76
  • RNTX N/A
  • Resistance Level
  • VHC $8.63
  • RNTX N/A
  • Average True Range (ATR)
  • VHC 0.42
  • RNTX 0.00
  • MACD
  • VHC -0.03
  • RNTX 0.00
  • Stochastic Oscillator
  • VHC 38.02
  • RNTX 0.00

About VHC VirnetX Holding Corp

VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: